 | • レポートコード：QY20ST-08832 • 出版社/出版日：QYResearch / 2020年9月25日 ※2025年版があります。お問い合わせください。 • レポート形態：英文、PDF、138ページ • 納品方法：Eメール（受注後2~3営業日） • 産業分類：医薬品、医療 |
| Single User | ￥560,000 (USD4,000) | ▷ お問い合わせ |
| Multi User | ￥840,000 (USD6,000) | ▷ お問い合わせ |
| Enterprise License | ￥1,120,000 (USD8,000) | ▷ お問い合わせ |
• お支払方法：銀行振込（納品後、ご請求書送付）
レポート概要
| 本調査レポートでは、世界の閉経後膣萎縮薬市場について種類別（膣用ジェル、クリーム、タブレット、リング、パッチ）、用途別（ Vaginal Gels Creams Tablets Rings Patches ）、地域別（北米、ヨーロッパ、中国、日本、東南アジア、インド）に区分して調査し、纏めました。2015年～2026年までの市場規模予測、主要プレイヤーの競争状況・市場シェア・企業情報、製造コスト分析、販売チャネル・流通業者・顧客情報、市場動向・機会・課題などのマーケットデータが記載されています。市場予測データは新型コロナウイルスの影響を反映させました。 ・閉経後膣萎縮薬市場の概要 ・世界の主要地域別閉経後膣萎縮薬市場規模2015-2026 ・主要プレイヤーの競争状況・市場シェア ・世界の閉経後膣萎縮薬市場規模2015-2026：種類別（膣用ジェル、クリーム、タブレット、リング、パッチ） ・世界の閉経後膣萎縮薬市場規模2015-2026：用途別（ Vaginal Gels Creams Tablets Rings Patches ） ・閉経後膣萎縮薬の北米市場規模2015-2020 ・閉経後膣萎縮薬のヨーロッパ市場規模2015-2020 ・閉経後膣萎縮薬の中国市場規模2015-2020 ・閉経後膣萎縮薬の日本市場規模2015-2020 ・閉経後膣萎縮薬の東南アジア市場規模2015-2020 ・閉経後膣萎縮薬のインド市場規模2015-2020 ・主要プレイヤーの企業情報：事業概要・売上・企業動向 ・閉経後膣萎縮薬の製造コスト分析 ・販売チャネル、流通業者、顧客 ・閉経後膣萎縮薬の市場動向・機会・課題 ・調査の結論 |
Postmenopausal vaginal atrophy (PVA) refers to reduction in estrogen production after menopause and this condition is also called as vaginal atrophy. Less estrogen leads to thinning, drying, and decreased elasticity of vaginal tissues. Various other factors that lead to decrease in estrogen levels include perimenopause during breast feeding, surgical menopause, pelvic radiation therapy, and chemotherapy.
Market Analysis and Insights: Global Postmenopausal Vaginal Atrophy Drugs Market
Since the COVID-19 virus outbreak in December 2019, the disease has spread to almost 100 countries around the globe with the World Health Organization declaring it a public health emergency. The global impacts of the coronavirus disease 2019 (COVID-19) are already starting to be felt, and will significantly affect the Postmenopausal Vaginal Atrophy Drugs market in 2020.
COVID-19 can affect the global economy in three main ways: by directly affecting production and demand, by creating supply chain and market disruption, and by its financial impact on firms and financial markets.
The outbreak of COVID-19 has brought effects on many aspects, like flight cancellations; travel bans and quarantines; restaurants closed; all indoor events restricted; over forty countries state of emergency declared; massive slowing of the supply chain; stock market volatility; falling business confidence, growing panic among the population, and uncertainty about future.
This report also analyses the impact of Coronavirus COVID-19 on the Postmenopausal Vaginal Atrophy Drugs industry.
Based on our recent survey, we have several different scenarios about the Postmenopausal Vaginal Atrophy Drugs YoY growth rate for 2020. The probable scenario is expected to grow by a xx% in 2020 and the revenue will be xx in 2020 from US$ xx million in 2019. The market size of Postmenopausal Vaginal Atrophy Drugs will reach xx in 2026, with a CAGR of xx% from 2020 to 2026.
Global Postmenopausal Vaginal Atrophy Drugs Scope and Market Size
The global Postmenopausal Vaginal Atrophy Drugs market is segmented by Type, and by Application. Players, stakeholders, and other participants in the global Postmenopausal Vaginal Atrophy Drugs market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on sales, revenue and forecast by Type and by Application for the period 2015-2026.
Segment by Type, the Postmenopausal Vaginal Atrophy Drugs market is segmented into
Premarin
Vagifem
Estrace
Estring
Femring
Segment by Application, the Postmenopausal Vaginal Atrophy Drugs market is segmented into
Vaginal Gels
Creams
Tablets
Rings
Patches
The Postmenopausal Vaginal Atrophy Drugs market is analysed and market size information is provided by regions (countries). Segment by Application, the Postmenopausal Vaginal Atrophy Drugs market is segmented into United States, Europe, China, Japan, Southeast Asia, India and Rest of World.
The report includes region-wise market size for the period 2015-2026. It also includes market size and forecast by players, by Type, and by Application segment in terms of sales and revenue for the period 2015-2026.
Competitive Landscape and Postmenopausal Vaginal Atrophy Drugs Market Share Analysis
Postmenopausal Vaginal Atrophy Drugs market competitive landscape provides details and data information by players. The report offers comprehensive analysis and accurate statistics on revenue by the player for the period 2015-2020. It also offers detailed analysis supported by reliable statistics on revenue (global and regional level) by players for the period 2015-2020. Details included are company description, major business, company total revenue and the sales, revenue generated in Postmenopausal Vaginal Atrophy Drugs business, the date to enter into the Postmenopausal Vaginal Atrophy Drugs market, Postmenopausal Vaginal Atrophy Drugs product introduction, recent developments, etc.
The major vendors covered:
Actavis plc
Bionovo, Inc.
Endoceutics, Inc.
Novo Nordisk A/S
Pfizer Inc.
Teva Pharmaceuticals Ltd.
Therapeutics MD, Inc.
Shionogi & Company
Allergan plc
Shionogi & Co. Ltd.
1 Postmenopausal Vaginal Atrophy Drugs Market Overview
1.1 Postmenopausal Vaginal Atrophy Drugs Product Scope
1.2 Postmenopausal Vaginal Atrophy Drugs Segment by Type
1.2.1 Global Postmenopausal Vaginal Atrophy Drugs Sales by Type (2020-2026)
1.2.2 Premarin
1.2.3 Vagifem
1.2.4 Estrace
1.2.5 Estring
1.2.6 Femring
1.3 Postmenopausal Vaginal Atrophy Drugs Segment by Application
1.3.1 Global Postmenopausal Vaginal Atrophy Drugs Sales Comparison by Application (2020-2026)
1.3.2 Vaginal Gels
1.3.3 Creams
1.3.4 Tablets
1.3.5 Rings
1.3.6 Patches
1.4 Postmenopausal Vaginal Atrophy Drugs Market Estimates and Forecasts (2015-2026)
1.4.1 Global Postmenopausal Vaginal Atrophy Drugs Sales Growth Rate (2015-2026)
1.4.2 Global Postmenopausal Vaginal Atrophy Drugs Revenue and Growth Rate (2015-2026)
1.4.3 Global Postmenopausal Vaginal Atrophy Drugs Price Trends (2015-2026)
1.5 Coronavirus Disease 2019 (Covid-19): Postmenopausal Vaginal Atrophy Drugs Industry Impact
1.5.1 How the Covid-19 is Affecting the Postmenopausal Vaginal Atrophy Drugs Industry
1.5.1.1 Postmenopausal Vaginal Atrophy Drugs Business Impact Assessment – Covid-19
1.5.1.2 Supply Chain Challenges
1.5.1.3 COVID-19’s Impact On Crude Oil and Refined Products
1.5.2 Market Trends and Postmenopausal Vaginal Atrophy Drugs Potential Opportunities in the COVID-19 Landscape
1.5.3 Measures / Proposal against Covid-19
1.5.3.1 Government Measures to Combat Covid-19 Impact
1.5.3.2 Proposal for Postmenopausal Vaginal Atrophy Drugs Players to Combat Covid-19 Impact
2 Postmenopausal Vaginal Atrophy Drugs Estimate and Forecast by Region
2.1 Global Postmenopausal Vaginal Atrophy Drugs Market Size by Region: 2015 VS 2020 VS 2026
2.2 Global Postmenopausal Vaginal Atrophy Drugs Retrospective Market Scenario by Region (2015-2020)
2.2.1 Global Postmenopausal Vaginal Atrophy Drugs Sales Market Share by Region (2015-2020)
2.2.2 Global Postmenopausal Vaginal Atrophy Drugs Revenue Market Share by Region (2015-2020)
2.3 Global Postmenopausal Vaginal Atrophy Drugs Market Estimates and Forecasts by Region (2021-2026)
2.3.1 Global Postmenopausal Vaginal Atrophy Drugs Sales Estimates and Forecasts by Region (2021-2026)
2.3.2 Global Postmenopausal Vaginal Atrophy Drugs Revenue Forecast by Region (2021-2026)
2.4 Geographic Market Analysis: Market Facts & Figures
2.4.1 United States Postmenopausal Vaginal Atrophy Drugs Estimates and Projections (2015-2026)
2.4.2 Europe Postmenopausal Vaginal Atrophy Drugs Estimates and Projections (2015-2026)
2.4.3 China Postmenopausal Vaginal Atrophy Drugs Estimates and Projections (2015-2026)
2.4.4 Japan Postmenopausal Vaginal Atrophy Drugs Estimates and Projections (2015-2026)
2.4.5 Southeast Asia Postmenopausal Vaginal Atrophy Drugs Estimates and Projections (2015-2026)
2.4.6 India Postmenopausal Vaginal Atrophy Drugs Estimates and Projections (2015-2026)
3 Global Postmenopausal Vaginal Atrophy Drugs Competition Landscape by Players
3.1 Global Top Postmenopausal Vaginal Atrophy Drugs Players by Sales (2015-2020)
3.2 Global Top Postmenopausal Vaginal Atrophy Drugs Players by Revenue (2015-2020)
3.3 Global Postmenopausal Vaginal Atrophy Drugs Market Share by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Postmenopausal Vaginal Atrophy Drugs as of 2019)
3.4 Global Postmenopausal Vaginal Atrophy Drugs Average Price by Company (2015-2020)
3.5 Manufacturers Postmenopausal Vaginal Atrophy Drugs Manufacturing Sites, Area Served, Product Type
3.6 Manufacturers Mergers & Acquisitions, Expansion Plans
3.7 Primary Interviews with Key Postmenopausal Vaginal Atrophy Drugs Players (Opinion Leaders)
4 Global Postmenopausal Vaginal Atrophy Drugs Market Size by Type
4.1 Global Postmenopausal Vaginal Atrophy Drugs Historic Market Review by Type (2015-2020)
4.1.1 Global Postmenopausal Vaginal Atrophy Drugs Sales Market Share by Type (2015-2020)
4.1.2 Global Postmenopausal Vaginal Atrophy Drugs Revenue Market Share by Type (2015-2020)
4.1.3 Global Postmenopausal Vaginal Atrophy Drugs Price by Type (2014-2020)
4.2 Global Postmenopausal Vaginal Atrophy Drugs Market Estimates and Forecasts by Type (2021-2026)
4.2.1 Global Postmenopausal Vaginal Atrophy Drugs Sales Forecast by Type (2021-2026)
4.2.2 Global Postmenopausal Vaginal Atrophy Drugs Revenue Forecast by Type (2021-2026)
4.2.3 Global Postmenopausal Vaginal Atrophy Drugs Price Forecast by Type (2021-2026)
5 Global Postmenopausal Vaginal Atrophy Drugs Market Size by Application
5.1 Global Postmenopausal Vaginal Atrophy Drugs Historic Market Review by Application (2015-2020)
5.1.1 Global Postmenopausal Vaginal Atrophy Drugs Sales Market Share by Application (2015-2020)
5.1.2 Global Postmenopausal Vaginal Atrophy Drugs Revenue Market Share by Application (2015-2020)
5.1.3 Global Postmenopausal Vaginal Atrophy Drugs Price by Application (2015-2020)
5.2 Global Postmenopausal Vaginal Atrophy Drugs Market Estimates and Forecasts by Application (2021-2026)
5.2.1 Global Postmenopausal Vaginal Atrophy Drugs Sales Forecast by Application (2021-2026)
5.2.2 Global Postmenopausal Vaginal Atrophy Drugs Revenue Forecast by Application (2021-2026)
5.2.3 Global Postmenopausal Vaginal Atrophy Drugs Price Forecast by Application (2021-2026)
3 North America Postmenopausal Vaginal Atrophy Drugs Market Facts & Figures
3.2 North America Postmenopausal Vaginal Atrophy Drugs Sales Market Share by Company (2015-2020)
3.3 North America Postmenopausal Vaginal Atrophy Drugs Sales Market Share by Type (2015-2020)
3.4 North America Postmenopausal Vaginal Atrophy Drugs Sales Market Share by Application (2015-2020)
4 Europe Postmenopausal Vaginal Atrophy Drugs Market Facts & Figures
4.2 Europe Postmenopausal Vaginal Atrophy Drugs Sales Market Share by Company (2015-2020)
4.3 Europe Postmenopausal Vaginal Atrophy Drugs Sales Market Share by Type (2015-2020)
4.4 Europe Postmenopausal Vaginal Atrophy Drugs Sales Market Share by Application (2015-2020)
5 China Postmenopausal Vaginal Atrophy Drugs Market Facts & Figures
5.2 China Postmenopausal Vaginal Atrophy Drugs Sales Market Share by Company (2015-2020)
5.3 China Postmenopausal Vaginal Atrophy Drugs Sales Market Share by Type (2015-2020)
5.4 China Postmenopausal Vaginal Atrophy Drugs Sales Market Share by Application (2015-2020)
6 Japan Postmenopausal Vaginal Atrophy Drugs Market Facts & Figures
6.2 Japan Postmenopausal Vaginal Atrophy Drugs Sales Market Share by Company (2015-2020)
6.3 Japan Postmenopausal Vaginal Atrophy Drugs Sales Market Share by Type (2015-2020)
6.4 Japan Postmenopausal Vaginal Atrophy Drugs Sales Market Share by Application (2015-2020)
7 Southeast Asia Postmenopausal Vaginal Atrophy Drugs Market Facts & Figures
7.2 Southeast Asia Postmenopausal Vaginal Atrophy Drugs Sales Market Share by Company (2015-2020)
7.3 Southeast Asia Postmenopausal Vaginal Atrophy Drugs Sales Market Share by Type (2015-2020)
7.4 Southeast Asia Postmenopausal Vaginal Atrophy Drugs Sales Market Share by Application (2015-2020)
8 India Postmenopausal Vaginal Atrophy Drugs Market Facts & Figures
8.2 India Postmenopausal Vaginal Atrophy Drugs Sales Market Share by Company (2015-2020)
8.3 India Postmenopausal Vaginal Atrophy Drugs Sales Market Share by Type (2015-2020)
8.4 India Postmenopausal Vaginal Atrophy Drugs Sales Market Share by Application (2015-2020)
12 Company Profiles and Key Figures in Postmenopausal Vaginal Atrophy Drugs Business
12.1 Actavis plc
12.1.1 Actavis plc Postmenopausal Vaginal Atrophy Drugs Corporation Information
12.1.2 Actavis plc Postmenopausal Vaginal Atrophy Drugs Business Overview and Total Revenue
12.1.3 Actavis plc Postmenopausal Vaginal Atrophy Drugs Sales, Revenue and Gross Margin (2015-2020)
12.1.4 Actavis plc Postmenopausal Vaginal Atrophy Drugs Products Offered
12.1.5 Actavis plc Recent Development
12.2 Bionovo, Inc.
12.2.1 Bionovo, Inc. Postmenopausal Vaginal Atrophy Drugs Corporation Information
12.2.2 Bionovo, Inc. Postmenopausal Vaginal Atrophy Drugs Business Overview and Total Revenue
12.2.3 Bionovo, Inc. Postmenopausal Vaginal Atrophy Drugs Sales, Revenue and Gross Margin (2015-2020)
12.2.4 Bionovo, Inc. Postmenopausal Vaginal Atrophy Drugs Products Offered
12.2.5 Bionovo, Inc. Recent Development
12.3 Endoceutics, Inc.
12.3.1 Endoceutics, Inc. Postmenopausal Vaginal Atrophy Drugs Corporation Information
12.3.2 Endoceutics, Inc. Postmenopausal Vaginal Atrophy Drugs Business Overview and Total Revenue
12.3.3 Endoceutics, Inc. Postmenopausal Vaginal Atrophy Drugs Sales, Revenue and Gross Margin (2015-2020)
12.3.4 Endoceutics, Inc. Postmenopausal Vaginal Atrophy Drugs Products Offered
12.3.5 Endoceutics, Inc. Recent Development
12.4 Novo Nordisk A/S
12.4.1 Novo Nordisk A/S Postmenopausal Vaginal Atrophy Drugs Corporation Information
12.4.2 Novo Nordisk A/S Postmenopausal Vaginal Atrophy Drugs Business Overview and Total Revenue
12.4.3 Novo Nordisk A/S Postmenopausal Vaginal Atrophy Drugs Sales, Revenue and Gross Margin (2015-2020)
12.4.4 Novo Nordisk A/S Postmenopausal Vaginal Atrophy Drugs Products Offered
12.4.5 Novo Nordisk A/S Recent Development
12.5 Pfizer Inc.
12.5.1 Pfizer Inc. Postmenopausal Vaginal Atrophy Drugs Corporation Information
12.5.2 Pfizer Inc. Postmenopausal Vaginal Atrophy Drugs Business Overview and Total Revenue
12.5.3 Pfizer Inc. Postmenopausal Vaginal Atrophy Drugs Sales, Revenue and Gross Margin (2015-2020)
12.5.4 Pfizer Inc. Postmenopausal Vaginal Atrophy Drugs Products Offered
12.5.5 Pfizer Inc. Recent Development
12.6 Teva Pharmaceuticals Ltd.
12.6.1 Teva Pharmaceuticals Ltd. Postmenopausal Vaginal Atrophy Drugs Corporation Information
12.6.2 Teva Pharmaceuticals Ltd. Postmenopausal Vaginal Atrophy Drugs Business Overview and Total Revenue
12.6.3 Teva Pharmaceuticals Ltd. Postmenopausal Vaginal Atrophy Drugs Sales, Revenue and Gross Margin (2015-2020)
12.6.4 Teva Pharmaceuticals Ltd. Postmenopausal Vaginal Atrophy Drugs Products Offered
12.6.5 Teva Pharmaceuticals Ltd. Recent Development
12.7 Therapeutics MD, Inc.
12.7.1 Therapeutics MD, Inc. Postmenopausal Vaginal Atrophy Drugs Corporation Information
12.7.2 Therapeutics MD, Inc. Postmenopausal Vaginal Atrophy Drugs Business Overview and Total Revenue
12.7.3 Therapeutics MD, Inc. Postmenopausal Vaginal Atrophy Drugs Sales, Revenue and Gross Margin (2015-2020)
12.7.4 Therapeutics MD, Inc. Postmenopausal Vaginal Atrophy Drugs Products Offered
12.7.5 Therapeutics MD, Inc. Recent Development
12.8 Shionogi & Company
12.8.1 Shionogi & Company Postmenopausal Vaginal Atrophy Drugs Corporation Information
12.8.2 Shionogi & Company Postmenopausal Vaginal Atrophy Drugs Business Overview and Total Revenue
12.8.3 Shionogi & Company Postmenopausal Vaginal Atrophy Drugs Sales, Revenue and Gross Margin (2015-2020)
12.8.4 Shionogi & Company Postmenopausal Vaginal Atrophy Drugs Products Offered
12.8.5 Shionogi & Company Recent Development
12.9 Allergan plc
12.9.1 Allergan plc Postmenopausal Vaginal Atrophy Drugs Corporation Information
12.9.2 Allergan plc Postmenopausal Vaginal Atrophy Drugs Business Overview and Total Revenue
12.9.3 Allergan plc Postmenopausal Vaginal Atrophy Drugs Sales, Revenue and Gross Margin (2015-2020)
12.9.4 Allergan plc Postmenopausal Vaginal Atrophy Drugs Products Offered
12.9.5 Allergan plc Recent Development
12.10 Shionogi & Co. Ltd.
12.10.1 Shionogi & Co. Ltd. Postmenopausal Vaginal Atrophy Drugs Corporation Information
12.10.2 Shionogi & Co. Ltd. Postmenopausal Vaginal Atrophy Drugs Business Overview and Total Revenue
12.10.3 Shionogi & Co. Ltd. Postmenopausal Vaginal Atrophy Drugs Sales, Revenue and Gross Margin (2015-2020)
12.10.4 Shionogi & Co. Ltd. Postmenopausal Vaginal Atrophy Drugs Products Offered
12.10.5 Shionogi & Co. Ltd. Recent Development
13 Postmenopausal Vaginal Atrophy Drugs Manufacturing Cost Analysis
13.1 Postmenopausal Vaginal Atrophy Drugs Key Raw Materials Analysis
13.1.1 Key Raw Materials
13.1.2 Key Raw Materials Price Trend
13.1.3 Key Suppliers of Raw Materials
13.2 Proportion of Manufacturing Cost Structure
13.3 Manufacturing Process Analysis of Postmenopausal Vaginal Atrophy Drugs
13.4 Postmenopausal Vaginal Atrophy Drugs Industrial Chain Analysis
14 Marketing Channel, Distributors and Customers
14.1 Marketing Channel
14.2 Postmenopausal Vaginal Atrophy Drugs Distributors List
14.3 Postmenopausal Vaginal Atrophy Drugs Customers
15 Market Dynamics
15.1 Market Trends
15.2 Opportunities and Drivers
15.3 Challenges
15.4 Porter’s Five Forces Analysis
16 Research Findings and Conclusion
17 Appendix
17.1 Research Methodology
17.1.1 Methodology/Research Approach
17.1.2 Data Source
17.2 Author List
17.3 Disclaimer
Table 1. Global Postmenopausal Vaginal Atrophy Drugs Sales (K Units) Growth Rate by Type (2020-2026)
Table 2. Global Postmenopausal Vaginal Atrophy Drugs Sales (K Units) Comparison by Application (2020-2026)
Table 3. COVID-19 Impact Global Market: (Four Postmenopausal Vaginal Atrophy Drugs Market Size Forecast Scenarios)
Table 4. Opportunities and Trends for Postmenopausal Vaginal Atrophy Drugs Players in the COVID-19 Landscape
Table 5. Present Opportunities in China & Elsewhere Due to the Coronavirus Crisis
Table 6. Key Regions/Countries Measures against Covid-19 Impact
Table 7. Proposal for Postmenopausal Vaginal Atrophy Drugs Players to Combat Covid-19 Impact
Table 8. Global Market Postmenopausal Vaginal Atrophy Drugs Market Size (US$ Million) by Region:2015 VS 2020 &2026
Table 9. Global Postmenopausal Vaginal Atrophy Drugs Sales (K Units) by Region (2015-2020)
Table 10. Global Postmenopausal Vaginal Atrophy Drugs Sales Market Share by Region (2015-2020)
Table 11. Global Postmenopausal Vaginal Atrophy Drugs Revenue (US$ Million) Market Share by Region (2015-2020))
Table 12. Global Postmenopausal Vaginal Atrophy Drugs Revenue Share by Region (2015-2020)
Table 13. Global Postmenopausal Vaginal Atrophy Drugs Sales (K Units) Forecast by Region (2021-2026)
Table 14. Global Postmenopausal Vaginal Atrophy Drugs Sales Market Share Forecast by Region (2021-2026)
Table 15. Global Postmenopausal Vaginal Atrophy Drugs Revenue (US$ Million) Forecast by Region (2021-2026)
Table 16. Global Postmenopausal Vaginal Atrophy Drugs Revenue Share Forecast by Region (2021-2026)
Table 17. Global Postmenopausal Vaginal Atrophy Drugs (K Units) of Key Companies (2015-2020)
Table 18. Global Postmenopausal Vaginal Atrophy Drugs Sales Share by Company (2015-2020)
Table 19. Global Postmenopausal Vaginal Atrophy Drugs Revenue (US$ Million) by Company (2015-2020)
Table 20. Global Postmenopausal Vaginal Atrophy Drugs Revenue Share by Company (2015-2020)
Table 21. Global Postmenopausal Vaginal Atrophy Drugs by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Postmenopausal Vaginal Atrophy Drugs as of 2019)
Table 22. Global Postmenopausal Vaginal Atrophy Drugs Average Price (USD/Unit) of Key Company (2015-2020)
Table 23. Manufacturers Postmenopausal Vaginal Atrophy Drugs Manufacturing Sites and Area Served
Table 24. Manufacturers Postmenopausal Vaginal Atrophy Drugs Product Type
Table 25. Manufacturers Mergers & Acquisitions, Expansion Plans
Table 26. Main Points Interviewed from Key Postmenopausal Vaginal Atrophy Drugs Players
Table 27. Global Postmenopausal Vaginal Atrophy Drugs Sales (K Units) by Type (2015-2020)
Table 28. Global Postmenopausal Vaginal Atrophy Drugs Sales Share by Type (2015-2020)
Table 29. Global Postmenopausal Vaginal Atrophy Drugs Revenue (US$ Million) Market Share by Type (2015-2020)
Table 30. Global Postmenopausal Vaginal Atrophy Drugs Price (K Units) by Type (2015-2020)
Table 31. Global Postmenopausal Vaginal Atrophy Drugs Sales Share by Type (2021-2026)
Table 32. Global Postmenopausal Vaginal Atrophy Drugs Revenue (US$ Million) Market Share by Type (2021-2026)
Table 33. Global Postmenopausal Vaginal Atrophy Drugs Revenue Share by Type (2021-2026)
Table 34. Global Postmenopausal Vaginal Atrophy Drugs Price (K Units) by Type (2021-2026)
Table 35. Global Postmenopausal Vaginal Atrophy Drugs Sales (K Units) by Application (2015-2020)
Table 36. Global Postmenopausal Vaginal Atrophy Drugs Sales Share by Application (2015-2020)
Table 37. Global Postmenopausal Vaginal Atrophy Drugs Revenue (US$ Million) Market Share by Application (2015-2020)
Table 38. Global Postmenopausal Vaginal Atrophy Drugs Price (K Units) by Application (2015-2020)
Table 39. Global Postmenopausal Vaginal Atrophy Drugs Sales (K Units) by Application (2021-2026)
Table 40. Global Postmenopausal Vaginal Atrophy Drugs Sales Share by Application (2021-2026)
Table 41. Global Postmenopausal Vaginal Atrophy Drugs Revenue (US$ Million) Market Share by Application (2021-2026)
Table 42. Global Postmenopausal Vaginal Atrophy Drugs Revenue Share by Application (2021-2026)
Table 43. Global Postmenopausal Vaginal Atrophy Drugs Price (K Units) by Application (2021-2026)
Table 44. United States Postmenopausal Vaginal Atrophy Drugs Sales (K Units) by Company (2015-2020)
Table 45. United States Postmenopausal Vaginal Atrophy Drugs Sales Market Share by Company (2015-2020)
Table 46. United States Postmenopausal Vaginal Atrophy Drugs Sales (K Units) by Type (2015-2020)
Table 47. United States Postmenopausal Vaginal Atrophy Drugs Sales Market Share by Type (2015-2020)
Table 48. United States Postmenopausal Vaginal Atrophy Drugs Sales (K Units) by Application (2015-2020)
Table 49. United States Postmenopausal Vaginal Atrophy Drugs Sales Market Share by Application (2015-2020)
Table 50. Europe Postmenopausal Vaginal Atrophy Drugs Sales (K Units) by Company (2015-2020)
Table 51. Europe Postmenopausal Vaginal Atrophy Drugs Sales Market Share by Company (2015-2020)
Table 52. Europe Postmenopausal Vaginal Atrophy Drugs Sales (K Units) by Type (2015-2020)
Table 53. Europe Postmenopausal Vaginal Atrophy Drugs Sales Market Share by Type (2015-2020)
Table 54. Europe Postmenopausal Vaginal Atrophy Drugs Sales (K Units) by Application (2015-2020)
Table 55. Europe Postmenopausal Vaginal Atrophy Drugs Sales Market Share by Type (2015-2020)
Table 56. China Postmenopausal Vaginal Atrophy Drugs Sales (K Units) by Company (2015-2020)
Table 57. China Postmenopausal Vaginal Atrophy Drugs Sales Market Share by Company (2015-2020)
Table 58. China Postmenopausal Vaginal Atrophy Drugs Sales (K Units) by Type (2015-2020)
Table 59. China Postmenopausal Vaginal Atrophy Drugs Sales Market Share by Type (2015-2020)
Table 60. China Postmenopausal Vaginal Atrophy Drugs Sales (K Units) by Application (2015-2020)
Table 61. China Postmenopausal Vaginal Atrophy Drugs Sales Market Share by Application (2015-2020)
Table 62. Japan Postmenopausal Vaginal Atrophy Drugs Sales (K Units) by Company (2015-2020)
Table 63. Japan Postmenopausal Vaginal Atrophy Drugs Sales Market Share by Company (2015-2020)
Table 64. Japan Postmenopausal Vaginal Atrophy Drugs Sales (K Units) by Type (2015-2020)
Table 65. Japan Postmenopausal Vaginal Atrophy Drugs Sales Market Share by Type (2015-2020)
Table 66. Japan Postmenopausal Vaginal Atrophy Drugs Sales (K Units) by Application (2015-2020)
Table 67. Japan Postmenopausal Vaginal Atrophy Drugs Sales Market Share by Application (2015-2020)
Table 68. Southeast Asia Postmenopausal Vaginal Atrophy Drugs Sales (K Units) by Company (2015-2020)
Table 69. Southeast Asia Postmenopausal Vaginal Atrophy Drugs Sales Market Share by Company (2015-2020)
Table 70. Southeast Asia Postmenopausal Vaginal Atrophy Drugs Sales (K Units) by Type (2015-2020)
Table 71. Southeast Asia Postmenopausal Vaginal Atrophy Drugs Sales Market Share by Type (2015-2020)
Table 72. Southeast Asia Postmenopausal Vaginal Atrophy Drugs Sales (K Units) by Type (2015-2020)
Table 73. Southeast Asia Postmenopausal Vaginal Atrophy Drugs Sales Market Share by Application (2015-2020)
Table 74. India Postmenopausal Vaginal Atrophy Drugs Sales (K Units) by Company (2015-2020)
Table 75. India Postmenopausal Vaginal Atrophy Drugs Sales Market Share by Company (2015-2020)
Table 76. India Postmenopausal Vaginal Atrophy Drugs Sales (K Units) by Type (2015-2020)
Table 77. India Postmenopausal Vaginal Atrophy Drugs Sales Market Share by Type (2015-2020)
Table 78. India Postmenopausal Vaginal Atrophy Drugs Sales (K Units) by Application (2015-2020)
Table 79. India Postmenopausal Vaginal Atrophy Drugs Sales Market Share by Application (2015-2020)
Table 80. Actavis plc Corporation Information
Table 81. Actavis plc Description and Business Overview
Table 82. Actavis plc Postmenopausal Vaginal Atrophy Drugs Sales (K Units), Revenue (Million USD), Price (USD/Unit) and Gross Margin (2015-2020)
Table 83. Actavis plc Postmenopausal Vaginal Atrophy Drugs Product
Table 84. Actavis plc Recent Development
Table 85. Bionovo, Inc. Corporation Information
Table 86. Bionovo, Inc. Description and Business Overview
Table 87. Bionovo, Inc. Postmenopausal Vaginal Atrophy Drugs Sales (K Units), Revenue (Million USD), Price (USD/Unit) and Gross Margin (2015-2020)
Table 88. Bionovo, Inc. Postmenopausal Vaginal Atrophy Drugs Product
Table 89. Bionovo, Inc. Recent Development
Table 90. Endoceutics, Inc. Corporation Information
Table 91. Endoceutics, Inc. Description and Business Overview
Table 92. Endoceutics, Inc. Postmenopausal Vaginal Atrophy Drugs Sales (K Units), Revenue (Million USD), Price (USD/Unit) and Gross Margin (2015-2020)
Table 93. Endoceutics, Inc. Postmenopausal Vaginal Atrophy Drugs Product
Table 94. Endoceutics, Inc. Recent Development
Table 95. Novo Nordisk A/S Corporation Information
Table 96. Novo Nordisk A/S Description and Business Overview
Table 97. Novo Nordisk A/S Postmenopausal Vaginal Atrophy Drugs Sales (K Units), Revenue (Million USD), Price (USD/Unit) and Gross Margin (2015-2020)
Table 98. Novo Nordisk A/S Postmenopausal Vaginal Atrophy Drugs Product
Table 99. Novo Nordisk A/S Recent Development
Table 100. Pfizer Inc. Corporation Information
Table 101. Pfizer Inc. Description and Business Overview
Table 102. Pfizer Inc. Postmenopausal Vaginal Atrophy Drugs Sales (K Units), Revenue (Million USD), Price (USD/Unit) and Gross Margin (2015-2020)
Table 103. Pfizer Inc. Postmenopausal Vaginal Atrophy Drugs Product
Table 104. Pfizer Inc. Recent Development
Table 105. Teva Pharmaceuticals Ltd. Corporation Information
Table 106. Teva Pharmaceuticals Ltd. Description and Business Overview
Table 107. Teva Pharmaceuticals Ltd. Postmenopausal Vaginal Atrophy Drugs Sales (K Units), Revenue (Million USD), Price (USD/Unit) and Gross Margin (2015-2020)
Table 108. Teva Pharmaceuticals Ltd. Postmenopausal Vaginal Atrophy Drugs Product
Table 109. Teva Pharmaceuticals Ltd. Recent Development
Table 110. Therapeutics MD, Inc. Corporation Information
Table 111. Therapeutics MD, Inc. Description and Business Overview
Table 112. Therapeutics MD, Inc. Postmenopausal Vaginal Atrophy Drugs Sales (K Units), Revenue (Million USD), Price (USD/Unit) and Gross Margin (2015-2020)
Table 113. Therapeutics MD, Inc. Postmenopausal Vaginal Atrophy Drugs Product
Table 114. Therapeutics MD, Inc. Recent Development
Table 115. Shionogi & Company Corporation Information
Table 116. Shionogi & Company Postmenopausal Vaginal Atrophy Drugs Sales (K Units), Revenue (Million USD), Price (USD/Unit) and Gross Margin (2015-2020)
Table 117. Shionogi & Company Description and Business Overview
Table 118. Shionogi & Company Postmenopausal Vaginal Atrophy Drugs Product
Table 119. Shionogi & Company Recent Development
Table 120. Allergan plc Corporation Information
Table 121. Allergan plc Postmenopausal Vaginal Atrophy Drugs Sales (K Units), Revenue (Million USD), Price (USD/Unit) and Gross Margin (2015-2020)
Table 122. Allergan plc Description and Business Overview
Table 123. Allergan plc Postmenopausal Vaginal Atrophy Drugs Product
Table 124. Allergan plc Recent Development
Table . Shionogi & Co. Ltd. Corporation Information
Table . Shionogi & Co. Ltd. Description and Business Overview
Table . Shionogi & Co. Ltd. Postmenopausal Vaginal Atrophy Drugs Sales (K Units), Revenue (Million USD), Price (USD/Unit) and Gross Margin (2015-2020)
Table . Shionogi & Co. Ltd. Postmenopausal Vaginal Atrophy Drugs Product
Table . Shionogi & Co. Ltd. Recent Development
Table 130. Production Base and Market Concentration Rate of Raw Material
Table 131. Key Suppliers of Raw Materials
Table 132. Postmenopausal Vaginal Atrophy Drugs Distributors List
Table 133. Postmenopausal Vaginal Atrophy Drugs Customers List
Table 134. Market Key Trends
Table 135. Key Opportunities and Drivers: Impact Analysis (2020-2026)
Table 136. Key Challenges
Table 137. Research Programs/Design for This Report
Table 138. Key Data Information from Secondary Sources
Table 139. Key Data Information from Primary Sources
List of Figures
Figure 1. Postmenopausal Vaginal Atrophy Drugs Product Picture
Figure 2. Global Postmenopausal Vaginal Atrophy Drugs Sales Market Share by Type in 2020 & 2026
Figure 3. Type I Product Picture
Figure 4. Type II Product Picture
Figure 5. Global Postmenopausal Vaginal Atrophy Drugs Market Share by Application in 2020 & 2026
Figure 6. Vaginal Gels Examples
Figure 7. Creams Examples
Figure 8. Tablets Examples
Figure 9. Rings Examples
Figure 10. Patches Examples
Figure 11. Global Postmenopausal Vaginal Atrophy Drugs Sales (K Units) Growth Rate (2015-2026)
Figure 12. Global Postmenopausal Vaginal Atrophy Drugs Revenue (US$ Million) Growth Rate (2015-2026)
Figure 13. Global Postmenopausal Vaginal Atrophy Drugs Price Trends Growth Rate (2015-2026) (USD/Unit)
Figure 14. Global Postmenopausal Vaginal Atrophy Drugs Revenue Market Share by Region: 2015 VS 2020
Figure 15. Global Postmenopausal Vaginal Atrophy Drugs Revenue Market Share by Region: 2021 VS 2026
Figure 16. United States Postmenopausal Vaginal Atrophy Drugs Revenue (Million USD) Growth Rate (2015-2026)
Figure 17. United States Postmenopausal Vaginal Atrophy Drugs Sales (K Units) Growth Rate (2015-2026)
Figure 18. Europe Postmenopausal Vaginal Atrophy Drugs Revenue (Million USD) Growth Rate (2015-2026)
Figure 19. Europe Postmenopausal Vaginal Atrophy Drugs Sales (Million USD) Growth Rate (2015-2026)
Figure 20. China Postmenopausal Vaginal Atrophy Drugs Revenue (Million USD) Growth Rate (2015-2026)
Figure 21. China Postmenopausal Vaginal Atrophy Drugs Sales (Million USD) and Growth Rate (2015-2026)
Figure 22. Japan Postmenopausal Vaginal Atrophy Drugs Revenue (Million USD) Growth Rate (2015-2026)
Figure 23. Japan Postmenopausal Vaginal Atrophy Drugs Sales (Million USD) Growth Rate (2015-2026)
Figure 24. Southeast Asia Postmenopausal Vaginal Atrophy Drugs Revenue (Million USD) Growth Rate (2015-2026)
Figure 25. Southeast Asia Postmenopausal Vaginal Atrophy Drugs Sales (Million USD) Growth Rate (2015-2026)
Figure 26. India Postmenopausal Vaginal Atrophy Drugs Revenue (Million USD) Growth Rate (2015-2026)
Figure 27. India Postmenopausal Vaginal Atrophy Drugs Sales (Million USD) Growth Rate (2015-2026)
Figure 28. Global 5 Largest Postmenopausal Vaginal Atrophy Drugs Players Market Share by Revenue in Postmenopausal Vaginal Atrophy Drugs 2015 & 2019
Figure 29. Postmenopausal Vaginal Atrophy Drugs Market Share by Company Type (Tier 1, Tier 2 and Tier 3): 2015 VS 2019
Figure 30. Global Postmenopausal Vaginal Atrophy Drugs Revenue Share by Type (2015-2020)
Figure 31. Global Postmenopausal Vaginal Atrophy Drugs Revenue Growth Rate by Type in 2015 & 2019
Figure 32. Global Postmenopausal Vaginal Atrophy Drugs Revenue Share by Application (2015-2020)
Figure 33. Global Postmenopausal Vaginal Atrophy Drugs Revenue Growth Rate by Application in 2015 & 2019
Figure 34. United States Postmenopausal Vaginal Atrophy Drugs Sales Market Share by Type in 2019
Figure 35. United States Postmenopausal Vaginal Atrophy Drugs Sales Market Share by Type in 2019
Figure 36. Europe Postmenopausal Vaginal Atrophy Drugs Sales Market Share by Company in 2019
Figure 37. Europe Postmenopausal Vaginal Atrophy Drugs Sales Market Share by Type in 2019
Figure 38. Europe Postmenopausal Vaginal Atrophy Drugs Sales Market Share by Application in 2019
Figure 39. China Postmenopausal Vaginal Atrophy Drugs Sales Market Share by Company in 2019
Figure 40. China Postmenopausal Vaginal Atrophy Drugs Sales Market Share by Type in 2019
Figure 41. China Postmenopausal Vaginal Atrophy Drugs Sales Market Share by Application in 2019
Figure 42. Japan Postmenopausal Vaginal Atrophy Drugs Sales Market Share by Company in 2019
Figure 43. Japan Postmenopausal Vaginal Atrophy Drugs Sales Market Share by Type in 2019
Figure 44. Japan Postmenopausal Vaginal Atrophy Drugs Sales Market Share by Application in 2019
Figure 45. Southeast Asia Postmenopausal Vaginal Atrophy Drugs Sales Market Share by Company in 2019
Figure 46. Southeast Asia Postmenopausal Vaginal Atrophy Drugs Sales Market Share by Type in 2019
Figure 47. Southeast Asia Postmenopausal Vaginal Atrophy Drugs Sales Market Share by Application in 2019
Figure 48. India Postmenopausal Vaginal Atrophy Drugs Sales Market Share by Company in 2019
Figure 49. India Postmenopausal Vaginal Atrophy Drugs Sales Market Share by Type in 2019
Figure 50. India Postmenopausal Vaginal Atrophy Drugs Sales Market Share by Application in 2019
Figure 51. Actavis plc Total Revenue (US$ Million): 2019 Compared with 2018
Figure 52. Bionovo, Inc. Total Revenue (US$ Million): 2019 Compared with 2018
Figure 53. Endoceutics, Inc. Total Revenue (US$ Million): 2019 Compared with 2018
Figure 54. Novo Nordisk A/S Total Revenue (US$ Million): 2019 Compared with 2018
Figure 55. Pfizer Inc. Total Revenue (US$ Million): 2019 Compared with 2018
Figure 56. Teva Pharmaceuticals Ltd. Total Revenue (US$ Million): 2019 Compared with 2018
Figure 57. Therapeutics MD, Inc. Total Revenue (US$ Million): 2019 Compared with 2018
Figure 58. Shionogi & Company Total Revenue (US$ Million): 2019 Compared with 2018
Figure 59. Allergan plc Total Revenue (US$ Million): 2019 Compared with 2018
Figure 60. Shionogi & Co. Ltd. Total Revenue (US$ Million): 2019 Compared with 2018
Figure 61. Key Raw Materials Price Trend
Figure 62. Manufacturing Cost Structure of Postmenopausal Vaginal Atrophy Drugs
Figure 63. Manufacturing Process Analysis of Postmenopausal Vaginal Atrophy Drugs
Figure 64. Postmenopausal Vaginal Atrophy Drugs Industrial Chain Analysis
Figure 65. Channels of Distribution
Figure 66. Distributors Profiles
Figure 67. Porter's Five Forces Analysis
Figure 68. Bottom-up and Top-down Approaches for This Report
Figure 69. Data Triangulation
Figure 70. Key Executives Interviewed
閉経後膣萎縮症（PVA）治療の世界市場 2020年：企業別、地域別、種類・用途別 Market Overview The Postmenopausal Vaginal Atrophy (PVA) Therapeutics market report provides a detailed analysis of global market size, regional and country-level market size, segmentation market growth, market share, competitive Landscape, sales analysis, impact of domestic and global market player…- 膣用アプリケーターの世界市場レポート2020 A recently published report by QY Research titled Global Vaginal Applicator Sales Market Report 2020 is designed in a way that helps the readers to acquire a complete knowledge about the overall market scenario and it’s most lucrative sectors. The research report also statistically provides accurate…
- 膣用アプリケーターの世界市場レポート2020 A recently published report by QY Research titled Global Vaginal Applicator Sales Market Report 2020 is designed in a way that helps the readers to acquire a complete knowledge about the overall market scenario and it’s most lucrative sectors. The research report also statistically provides accurate…
- 膣レトラクタの世界市場レポート2020 A recently published report by QY Research titled Global Vaginal Retractor Sales Market Report 2020 is designed in a way that helps the readers to acquire a complete knowledge about the overall market scenario and it’s most lucrative sectors. The research report also statistically provides accurate …
- 膣鏡の世界市場 2020年：メーカー別、地域別、種類・用途別 Market Overview The Vaginal Speculum market report provides a detailed analysis of global market size, regional and country-level market size, segmentation market growth, market share, competitive Landscape, sales analysis, impact of domestic and global market players, value chain optimization, trad…